Vertical Metabolome Transfer from Mother to Child: An Explainable Machine Learning Method for Detecting Metabolomic Heritability

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 2,04 MB, PDF-dokument

Vertical transmission of metabolic constituents from mother to child contributes to the manifestation of disease phenotypes in early life. This study probes the vertical transmission of metabolites from mothers to offspring by utilizing machine learning techniques to differentiate between true mother–child dyads and randomly paired non-dyads. Employing random forests (RF), light gradient boosting machine (LGBM), and logistic regression (Elasticnet) models, we analyzed metabolite concentration discrepancies in mother–child pairs, with maternal plasma sampled at 24 weeks of gestation and children’s plasma at 6 months. The propensity of vertical transfer was quantified, reflecting the likelihood of accurate mother–child matching. Our findings were substantiated against an external test set and further verified through statistical tests, while the models were explained using permutation importance and SHapley Additive exPlanations (SHAP). The best model was achieved using RF, while xenobiotics were shown to be highly relevant in transfer. The study reaffirms the transmission of certain metabolites, such as perfluorooctanoic acid (PFOA), but also reveals additional insights into the maternal influence on the child’s metabolome. We also discuss the multifaceted nature of vertical transfer. These machine learning-driven insights complement conventional epidemiological findings and offer a novel perspective on using machine learning as a methodology for understanding metabolic interactions.

OriginalsprogEngelsk
Artikelnummer136
TidsskriftMetabolites
Vol/bind14
Udgave nummer3
Antal sider15
ISSN2218-1989
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
B.C. received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (grant agreement No. 946228). J.L.-S. received funding from the National Heart, Lung, and Blood Institute (NHLBI) grant R01HL123915 and R01HL141826. COPSAC is funded by private and public research funds, all listed on www.copsac.com. The Lundbeck Foundation, the Novo Nordisk Foundation, the Danish Ministry of Health, the Danish Council for Strategic Research, and the Capital Region Research Foundation provided core support for COPSAC. M.A.R. received funding from the Novo Nordisk Foundation (Grant nb: NNF21OC0068517).

Publisher Copyright:
© 2024 by the authors.

ID: 387701258